The Journal of Emergency Medicine
Volume 23, Issue 1 , Pages 23-33 , July 2002

Malaria: a rising incidence in the United States

  • David A Jerrard, MD

      Affiliations

    • Corresponding Author InformationReprint Address: David Jerrard, MD, 27 Brett Manor Court, Hunt Valley, MD 21030 USA
    • University of Maryland School of Medicine, Baltimore, Maryland, USA
    • ,
  • Joshua S Broder, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland, USA
    • ,
  • Jeahan R Hanna, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland, USA
    • ,
  • James E Colletti, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland, USA
    • ,
  • Katherine A Grundmann, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland, USA
    • ,
  • Adam J Geroff, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland, USA
    • ,
  • Amal Mattu, MD

      Affiliations

    • University of Maryland School of Medicine, Baltimore, Maryland, USA

Received 13 July 2001 ,Revised 3 December 2001 ,Accepted 8 January 2002.

References 

  1. World Health Organization . World Malaria Situation in 1993. Weekly Epidemiol Rec. 1996;71:17–24
  2. Zucker J. Changing patterns of autochthonous malaria transmission in the United States (a review of recent outbreaks). Emerg Infect Dis. 1996;2:37–43
  3. Levinson W, Jawetz E. Blood and tissue protozoa. In:  Levinson W,  Jawetz E editor. Medical microbiology and immunology. 4th ed.. Norwalk: Appleton and Lange; 1996;p. 274–276
  4. Samuelson J, von Lichtenberg F. Infectious disease. In:  Cotran R,  Kumar V,  Robbins S editor. Pathologic basis of disease. 5th ed.. Philadelphia: W. B. Saunders Co; 1994;p. 362–363
  5. White N, Breman J. Malaria and babesiosis. In:  Isselbacher K,  Braunwald E,  Wilson J,  Martin J,  Fauci A,  Kasper D editor. Harrison’s principles of internal medicine. 13th ed.. New York: McGraw Hill; 1994;p. 887–896
  6. Warrell D, Molyneaux M, Beales P. Severe and complicated malaria. Trans R Soc Trop Med Hyg. 1990;84(Suppl):1–65
  7. Steketee R, Wirima J, Slutsker L, et al.  Objectives and methodology in a study of malaria treatment and prevention in pregnancy in rural Malawi (the Mangochi malaria research project). Am J Trop Med Hyg. 1996;55:17–23
  8. Procop N, Jessen R, Hyde S, et al.  The persistence of Plasmodium falciparum in the placenta after apparently effective quinidine/clindamycin therapy. J Perinatol. 2001;21:128–130
  9. Nosten F, ter Kuile F, Maelankiri L, et al.  Mefloquine prophylaxis prevents malaria during pregnancy (a double blind, placebo-controlled study). J Infect Dis. 1994;169:595–603
  10. White N, Ho M. The pathophysiology of malaria. Adv Parasitol. 1992;31:34–173
  11. Nosten F, McGready R, Simpson J, et al.  Effects of Plasmodium vivax malaria in pregnancy. Lancet. 1999;354:546–549
  12. Steketee R, Wirima J, Slutsker L, et al.  The problem of malaria and malaria control in pregnancy in sub-Saharan Africa. Am J Trop Med Hyg. 1996;55:2–7
  13. Steketee R, Wirima J, Slutsker L, et al.  Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi. Am J Trop Med Hyg. 1996;55:17–23
  14. Bloland P, Slutsker L, Steketee R, et al.  Rates and risk factors for mortality during the first two years of life in rural Malawi. Am J Trop Med Hyg. 1996;55:82–86
  15. Watkinson M, Rushton D. Plasmodial pigmentation of placenta and outcome of pregnancy in West African mothers. BMJ. 1983;287:251–254
  16. Bradley D, Warhurst D, Blaze M, et al.  Malaria imported into the United Kingdom. Eurosurveillance. 1996;3:40–42
  17. Apitzsch L, Rasch G, Kiehl W. Imported malaria in Germany in 1996. Eurosurveillance. 1998;3:35–36
  18. Centers for Disease Control and Prevention . Recommendations for the prevention of malaria among travelers. MMWR. 1990;39:1–10
  19. Chiodini P. Non-microscopic methods for the diagnosis of malaria. Lancet. 1998;351:80–81
  20. Hänscheid T. Diagnosis of malaria (a review of alternatives to conventional microscopy). Clin Lab Haem. 1999;21:235–245
  21. Milne L, Kyi M, Chiodini P, et al.  Accuracy of routine laboratory diagnosis of malaria in the United Kingdom. J Clin Path. 1994;47:740–742
  22. Durrheim D, la Grange J, Govere J. Accuracy of a rapid immunochromatographic card test for Plasmodium falciparum in a malaria control programme in South Africa. Trans R Soc Trop Med Hyg. 1998;92:31–33
  23. Caraballo A, Ache A. The evaluation of a dipstick test for Plasmodium falciparum in mining areas of Venezuela. Am J Trop Med Hyg. 1996;55:482–484
  24. Craig M, Sharp B. Comparative evaluation of four techniques for the diagnosis of Plasmodium falciparum infection. Trans R Soc Trop Med Hyg. 1997;91:279–282
  25. Diperri G, Olliaro P, Nardi S, et al.  The Parasight-F rapid dipstick antigen capture assay for monitoring parasite clearance after drug treatment of Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 1997;91:403–405
  26. Kodisinghe H, Perera K, Premawansa S, et al.  The Parasight-F dipstick as a routine diagnostic tool for malaria in Sri Lanka. Trans R Soc Trop Med Hyg. 1997;91:398–402
  27. Bain B, Chiodini P, England J. The laboratory diagnosis of malaria. Clin Lab Haem. 1997;19:165–170
  28. Humar A, Ohrt C, Harringon M. Parasight-F test compared with the polymerase chain reaction and microscopy for the diagnosis of Plasmodium falciparum malaria in travelers. Am J Trop Med Hyg. 1997;56:44–48
  29. Beadle C, Long G, Weiss W, et al.  Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet. 1994;334:564–568
  30. Shiff C, Minjas J, Premji Z. The Parasight-F test (a simple rapid manual dipstick test to detect Plasmodium falciparum infection). Parasitology Today. 1994;10:494–495
  31. Singh N, Valecha N, Sharma V. Malaria diagnosis by field workers using an immunochromatographic test. Trans R Soc Trop Med Hyg. 1997;91:396–397
  32. Mhara Kurwa S, Manyame B, Schiff C. Trial of the Parasight-F test for malaria diagnosis in the primary health care system. Zimbabwe. Trop Med Int Health. 1997;2:544–550
  33. Mhara Kurwa S, Shiff C. Post treatment studies with the Parasight-F test for malaria diagnosis in Zimbabwe. Acta Trop. 1997;66:61–67
  34. Laferi H, Kandel K, Pichler M. False positive dipstick test for malaria (letter). N Engl J Med. 1997;337:1635–1636
  35. Makler M, Piper R, Milhous W. Lactate dehydrogenase and the diagnosis of malaria. Parasitology Today. 1998;14:376–378
  36. Palmer C, Linda J, Klaskala W, et al.  Evaluation of the OptiMAL test for rapid diagnosis of Plasmodium vivax and Plasmodium falciparum. J. Clin Micro. 1998;36:203–206
  37. Jelinek T, Kilian A, Henk M, et al.  Parasite specific lactate dehydrogenase for the diagnosis of Plasmodium falciparum infection in an endemic area in West Uganda. Trop Med Int Health. 1996;1:227–230
  38. Knoblach J, Henk M. Screening for malaria by determination of parasite-specific lactate dehydrogenase. Trans R Soc Trop Med Hyg. 1995;89:269–270
  39. Grobush M, Alpermann U, Schwenke S, et al.  False-positive rapid tests for malaria in patients with rheumatoid factor. Lancet. 1999;353:297
  40. Seesod N, Nopparat P, Hedrum A, et al.  An integrated system using immunomagnetic separation polymerase-chain reaction and colorimetric detection for diagnosis of Plasmodium falciparum. Am J Trop Med Hyg. 1997;56:322–328
  41. Snounou G, Viriyakosol S, Jarra W, et al.  Identification of the four human malaria parasite species in field samples by the polymerase-chain-reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol. 1993;58:283–292
  42. Olivera D, Shi Y, Oloo A, et al.  Field evaluation of a polymerase-chain-reaction based nonisotopic liquid hybridization assay for malaria diagnosis. J Infect Dis. 1996;173:1284–1287
  43. Wernsdorfer W. Epidemiology of drug resistance in malaria. Acta Trop. 1994;56:143–156
  44. Campbell C, Chin W, Collins W, et al.  Chloroquine-resistant Plasmodium falciparum from East Africa. Cultivation and drug sensitivity of the Tanzanian 1/CDC stain from an American tourist. Lancet ii. 1979;1151–1154
  45. Bloland P, Lackritz E, Kazembe P, et al.  Beyond choloroquine (implications for evaluating malaria therapy efficacy and treatment policy in Africa). J Infect Dis. 1993;167:932–937
  46. Nwanyanwu O, Ziba C, Kazembe P. Efficacy of sulfadoxine/pyrimethamine for Plasmodium falciparum in Malawian children under five years of age. Trop Med Int Health. 1996;1:231–235
  47. Mockenhaupt F. Mefloquine resistance in Plasmodium falciparum. Parasitology Today. 1995;11:248–253
  48. Steffen R, Fuchs E, Schildknecht J, et al.  Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa. Lancet. 1993;341:1299–1303
  49. Lobel H, Miani M, Eng T. Long-term malaria prophylaxis with weekly mefloquine. Lancet. 1993;341:848–851
  50. Advice for Travelers. Med Lett. 1995;37:99–108
  51. Chamberland M, Duperval R, Marcoux J. Severe falciparum malaria in nonendemic areas (an unrecognized medical emergency). Can Med Assoc J. 1991;144:455–458
  52. Kain K. Chemotherapy and prevention of drug-resistant malaria. Wilderness Env Med. 1995;6:307–324
  53. White N. The treatment of malaria. N Engl J Med. 1996;335:800–806
  54. Garg M, Gopinathan N, Bodhe P, et al.  Vivax malaria resistant to chloroquine (case reports from Bombay). Trans R Soc Trop Med Hyg. 1995;89:656–657
  55. Marlar-Than , Myatt-Phone-Kyan , Aye-Yu-Soe , et al.  Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg. 1995;89:307–308
  56. Phillips E, Keystone J, Kain K. Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin Infect Dis. 1996;23:1171–1173
  57. Murphy G, Basri H, Purnomo T, et al.  Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet. 1993;341:96–100
  58. Alecrim M, Alecrim W, Macêdo V. Plasmodium vivax resistance to chloquinine (R2) and mefloquine (R3) in Brazilian Amazon region. Rev Soc Braz Med Trop. 1999;32:67–68
  59. Ronn A, Msangeni H, Mhina J, et al.  High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg. 1996;90:179–181
  60. Wolday D, Kilbreab T, Bukenya D, et al.  Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Trans R Soc Trop Med Hyg. 1995;89:654–656
  61. Darlow B, Vrobova H, Gibney S, et al.  Sulfadoxine-pyri-methamine for the treatment of acute malaria in children of Papua, New Guinea II. Plasmodium vivax. Am J Trop Med Hyg. 1982;31:10–13
  62. Drugs for parasitic infections. Med Lett. 1995;37:99–108
  63. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, et al.  Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet. 1991;337:1140–1143
  64. Looareesuwans S, Wiravan C, Vanijanonta S, et al.  Randomized trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria. Lancet. 1992;339:821–824
  65. ter Kuile F, Nosten F, Thieren M, et al.  High-dose mefloquine in the treatment of multi-drug resistant falciparum malaria. J Infect Dis. 1992;166:1393–1400
  66. ter Kuile F, Dolan G, Nosten F, et al.  Halofantrine versus mefloquine in treatment of multidrug resistant falciparum malaria. Lancet. 1993;341:1044–1049
  67. Nosten F, ter Kuile F, Luxemberger C, et al.  Cardiac effects of antimalarial treatment with halofantrine. Lancet. 1991;341:1054–1056
  68. Pukrittayakamee S, Supanaranond W, Looareesuwan S, et al.  Quinine in severe falciparum malaria (evidence of declining efficacy in Thailand). Trans R Soc Trop Med Hyg. 1996;88:324–327
  69. Brasseur P, Kouamovo J, Brandicourt O, et al.  Patterns of in vitro resistance to chloroquine, quinine and mefloquine of Plasmodium falciparum in Cameroon. 1985–1986. Am J Trop Med Hyg. 1988;39:166–172
  70. Jelinek T, Schelbert P, Loscher T, et al.  Quinine resistant falciparum malaria acquired in East Africa. Trop Med Parasitol. 1995;46:38–40
  71. White N. The treatment of malaria. N Engl J Med. 1996;335:800–806
  72. Luxemberger C, ter Kuile F, Nosten F, et al.  Single day mefloquine-artesunate combination in the treatment of multidrug resistant falciparum malaria. Trans R Soc Trop Med Hyg. 1994;88:213–217
  73. Schwartz E, Regev-Yochay G, Kurnik D. Short report (a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria). Am J Trop Med Hyg. 2000;62:393–395
  74. Pradines B, Spiegel A, Rogier C, et al.  Antibiotics for prophylaxis of Plasmodium falciparum infections (in vitro activity of doxycycline against senegalese isolates). Am J Trop Med Hyg. 2000;62:82–85
  75. Shanks G, Edstein M, Suriyamongkol V, et al.  Malaria chemoprophylaxis using proguanil/dapsone combinations on Thai-Cambodian border. Am J Trop Med Hyg. 1992;46:643–648
  76. Ohrt C, Richie T, Widjaja H, et al.  Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. Ann Intern Med. 1997;126:963–972
  77. Andersen S, Oloo A, Gordon D, et al.  Successful double-blinded, randomized, placebo-controlled field trials of azithromycin and doxycycline as prophylaxis for malaria in Western Kenya. Clin Infect Dis. 1998;26:146–150
  78. Baudon D, Martet G, Pascal B, et al.  Efficacy of daily antimalarial chemoprophylaxis in tropical Africa using either doxycycline or chloroquine-proguanil; study conducted in 1996 in the French Army. Trans R Soc Trop Med Hyg. 1996;93:1–2
  79. Weiss W, Oloo , Johnson A, et al.  Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya. Comparison with mefloquine, doxycycline and chloroquine plus proguanil. J Infect Dis. 1995;171:1569–1571
  80. Kremsner P, Winkler S, Brandts C, et al.  Clindamycin in combination with chloroquine on quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis. 1994;169:467–470
  81. Vaillant M, Millet P, Luty A, et al.  Therapeutic efficacy of clindamycin in combination with quinine for treating uncomplicated malaria in a village dispensary in Gabon. Trop Med Int Health. 1997;2:917–920
  82. Pukrittayakamee S, Chantra A, Vanijanonta S, et al.  Therapeutic responses to quinine and clindamycin in multi-drug resistant falciparum malaria. Antimicrob Agents and Chemo. 2000;44:2395–2398
  83. Nosten F, Luxemburger C, ter Kuile F, et al.  Treatment of multi-drug resistant Plasmodium falciparum malaria with 3 day artesunate-mefloquine combination. J Infect Dis. 1994;170:971–974
  84. White N. Artemisinin (current status). Trans R Soc Trop Med Hyg (Suppl). 1994;88:3–4
  85. Greenberg A, Lobel A. Mortality from Plasmodium falciparum malaria in travelers from the United States:1959–1987. Ann Intern Med. 1990;113:326–327
  86. Magill A, Smoak B. Failure of mefloquine chemoprophylaxis for malaria in Somalia. N Engl J Med. 1993;329:1206
  87. MacArthur J, Levin A, Roberts J, et al.  Malaria surveillance-United States, 1997. In CDC surveillance summaries (March 30). MMWR. 2001;50(No. SS-1):25–29
  88. Graves P. Comparison of the cost-effectiveness of vaccines and insecticide impregnation of mosquito nets for the prevention of malaria. Ann Trop Med Parasitol. 1998;92:399–440
  89. Engers H, Godal T. Malaria vaccine development (current status). Parasitol Today. 1998;14:56–64
  90. Stanley S. Malaria vaccines (are seven antigens better than one?). Lancet. 1998;352:1163–1164
  91. Tine J, Lanar D, Smith D, et al.  NYVAC-Pf7, a pox-virus-vectored, multiantigen multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immuno. 1996;64:3833–3844
  92. Ockenhouse C, Sun P, Lanar D, et al.  Phase I/IIa safety, immunogenicity, and efficacy of NYVAC-Pf7, a pox-vectored multi-anti-gen, multi-stage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis. 1998;177:1664–1673
  93. Cheng Q, Cloonan N, Fischer K, et al.  Stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol Biochem Parasitol. 1998;97:161–176
  94. Saul A, Lawrence G, Smillie A, et al.  Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA 720 Adjuvant. Vaccine. 1999;17:3145–3159
  95. Lawrence G, Cheng Q, Reed C, et al.  Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine. 2000;18:1925–1931
  96. Centers for Disease Control and Prevention . In: Health information for international travel - 1995. Atlanta: U. S. Department of Health and Human Services, Public Health Service; 1995;p. 1–204

PII: S0736-4679(02)00457-2

The Journal of Emergency Medicine
Volume 23, Issue 1 , Pages 23-33 , July 2002

Article Tools

* Image Usage & Resolution